Salman Muhammad, Khan Amer Hayat, Adnan Azreen Syazril, Syed Sulaiman Syed Azhar, Shehzadi Naureen, Asif Nauman, Hussain Khalid, Saleem Fahad, Raza Muhammed Hussnain, Farooq Muhammad Shahid
Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia; Department of Pharmacy Practice, Punjab University College of Pharmacy, University of the Punjab, Lahore, Pakistan.
Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Saudi J Kidney Dis Transpl. 2017 May-Jun;28(3):517-523. doi: 10.4103/1319-2442.206451.
Chronic kidney disease (CKD) patients suffer from multiple comorbidities and complications as a cause or consequence of kidney disease. Information regarding medication- prescribing patterns in predialysis patients is sparse. We conducted a retrospective study to evaluate the medication prescription patterns among predialysis patients. Medical records (both paper based and computerized) of patients at CKD Resource Centre, Hospital Universiti Sains Malaysia, were reviewed. A total of 615 eligible cases were included in the study. The mean number of medications prescribed per patient was 8.22 ± 2.81, and medication use was correlated to the renal function (stage 3a < stage 3b < stage 4 < stage 5; P <0.001). The top three prescribed medication groups were found to be lipid-lowering agents, calcium channel blockers, and antiplatelet agents. Some medication classes such as nonaluminum/noncalcium phosphate binders, erythropoietin-stimulating agents, and renin-angiotensin-aldosterone system blockers, particularly in advanced stage, were found to be underutilized. In conclusion, predialysis patients are prescribed a large number of medications. Our findings highlight the need for assessing the impact of current medication-prescribing patterns on morbidity and mortality rates in Malaysian predialysis population.
慢性肾脏病（CKD）患者会因肾脏疾病的病因或后果而患有多种合并症和并发症。关于透析前患者用药处方模式的信息很少。我们进行了一项回顾性研究，以评估透析前患者的用药处方模式。我们查阅了马来西亚理科大学医院CKD资源中心患者的病历（纸质和电子病历）。共有615例符合条件的病例纳入研究。每位患者的平均用药数量为8.22±2.81，用药情况与肾功能相关（3a期<3b期<4期<5期；P<0.001）。发现前三大类处方药物为降脂药、钙通道阻滞剂和抗血小板药。一些药物类别，如非铝/非钙磷结合剂、促红细胞生成素、肾素-血管紧张素-醛固酮系统阻滞剂，尤其是在晚期，发现使用不足。总之，透析前患者被开了大量药物。我们的研究结果强调了评估当前用药处方模式对马来西亚透析前人群发病率和死亡率影响的必要性。
